Cingulate (NASDAQ:CING – Get Free Report) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to post earnings of ($0.63) per share and revenue of $0.1670 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 20, 2026 at 9:30 AM ET.
Cingulate (NASDAQ:CING – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.42). On average, analysts expect Cingulate to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Cingulate Price Performance
NASDAQ:CING opened at $5.25 on Tuesday. The firm has a 50-day moving average of $4.88 and a 200-day moving average of $5.60. The company has a market cap of $70.72 million, a PE ratio of -1.24 and a beta of -0.90. Cingulate has a one year low of $3.16 and a one year high of $11.89.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on CING
Institutional Trading of Cingulate
A number of institutional investors and hedge funds have recently modified their holdings of CING. XTX Topco Ltd bought a new stake in Cingulate during the second quarter worth $45,000. Bank of America Corp DE grew its stake in Cingulate by 283.1% in the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock valued at $31,000 after purchasing an additional 5,543 shares during the period. Geode Capital Management LLC grew its stake in Cingulate by 43.9% in the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock valued at $265,000 after purchasing an additional 18,629 shares during the period. DRW Securities LLC purchased a new stake in shares of Cingulate during the 4th quarter valued at $255,000. Finally, Kestra Advisory Services LLC increased its position in shares of Cingulate by 29.8% during the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock valued at $529,000 after purchasing an additional 27,979 shares during the last quarter. 41.31% of the stock is owned by hedge funds and other institutional investors.
Cingulate Company Profile
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
Featured Articles
- Five stocks we like better than Cingulate
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
-B3.png){kind=small}
